Family medicine clinicians initiating GLP-1 therapy currently lack reliable tools to anticipate which patients will achieve meaningful weight loss versus those who will discontinue due to adverse effects, making empirical prescribing the default approach. A genetically informed predictive framework derived from a population of nearly 28,000 real-world GLP-1 users could allow clinicians to stratify patients before initiation, optimizing candidate selection and reducing unnecessary exposure in poor responders. This has direct implications for shared decision-making, resource utilization, and managing the high attrition rates that undermine long-term metabolic outcomes in primary care settings.

This study examined genetic predictors of both weight loss response and adverse effects among individuals taking GLP-1 receptor agonists for obesity, drawing on self-reported data from approximately 28,000 23andMe users who indicated they had used these medications. The research leveraged genome-wide association approaches to identify variants potentially associated with differential outcomes, including magnitude of weight loss and the likelihood of experiencing gastrointestinal side effects commonly reported with this drug class. The scale of the cohort is notable given the difficulty of assembling large pharmacogenomic datasets for a relatively recent class of agents, and the study represents one of the larger efforts to date to characterize the genetic architecture underlying interindividual variability in GLP-1 response.

Key findings suggested that specific genetic variants were associated with both the degree of weight reduction achieved and susceptibility to adverse effects, though granular effect sizes and precise variant-level data were not fully detailed in the available abstract. The identification of heritable predictors of response aligns with broader pharmacogenomic hypotheses that receptor biology, gut motility pathways, and appetite-regulating circuits carry genetic influences that could meaningfully stratify patient outcomes prior to treatment initiation. If replicated and validated prospectively, such markers could theoretically inform clinical decision-making around patient selection and counseling.

Several limitations warrant caution in interpreting these findings. The dataset relies entirely on self-reported medication use and self-reported outcomes from a direct-to-consumer genetic testing platform, introducing substantial ascertainment bias and precluding rigorous phenotypic standardization. Participants in 23andMe cohorts skew toward individuals with higher socioeconomic status, European ancestry, and health engagement behaviors, limiting generalizability across diverse clinical populations. The absence of dose information, treatment duration, concomitant interventions, and clinician-verified diagnoses further constrains the internal validity of the associations identified, and independent replication in prospectively enrolled clinical cohorts will be essential before these findings carry any translational weight.

Emerging research suggests that genetic variation may influence both how much weight a patient loses on GLP-1 therapy and how likely they are to experience side effects. A large-scale analysis of nearly 28,000 individuals identified specific genetic markers associated with differential treatment response, pointing toward a future where prescribing decisions may be informed by a patient’s genomic profile. While this science is still developing and is not yet ready for routine clinical use, it reinforces that variable outcomes on GLP-1 medications have a biological basis beyond lifestyle factors. When patients express frustration about slower weight loss or troublesome side effects compared to others on the same medication, clinicians can use this evidence to explain that individual genetic differences likely play a meaningful role, helping to reduce self-blame and improve therapeutic adherence.

“The promise of pharmacogenomics meeting GLP-1 therapy is something I’ve been watching closely, and a dataset of nearly 28,000 real-world users is genuinely meaningful signal. If we can identify genetic variants that predict both therapeutic response and adverse effect burden before we write the first prescription, we move from trial-and-error dosing to precision metabolic medicine. In my practice, this kind of data would fundamentally change the intake conversation, allowing me to tell a patient with reasonable confidence whether they are likely to be a strong responder or whether nausea and GI intolerance are going to be a significant barrier we need to plan around from day one. We are not there yet clinically, but this research trajectory is exactly where the field needs to go.”

? Join the Conversation

Have a question about how this applies to your situation? Ask Dr. Caplan →

Want to discuss this topic with other patients and caregivers? Join the forum discussion →

Have thoughts on this? Share it: